Asia-Pacific cardiology market is projected to grow significantly at a CAGR of around 7.0% during the forecast period. The market is mainly driven owing to the large population with CVD, CHD, Stroke and other heart diseases. The other factors contributing to the market include rising healthcare spending, improving infrastructure and rising standards of living. China, India, Japan, Australia, Korea, and Taiwan are the key economies growing at a significant rate due to the increasing demand for cardiology surgeries and devices. Along with that the rising adoption of innovative cardiology surgeries, robotic automation, and growing medical tourism in the region further provide ample opportunity for the growing market in the region.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-cardiology-market
The market is segmented on the basis of device type, drug type, mechanism, and surgeries type. Based on device type, the market is segregated angioplasty, cardiovascular stents, cardiovascular catheters, cardiac rhythm management, cardiovascular assistive devices. Angioplasty and vascular stenting are widely adopted procedures in the cardiology market and have a considerable market share. Based on the drug type, the market is segmented into antithrombotic drugs, antidyslipidemic drugs, antihypertensive drugs, and anti-stroke drugs. On the basis of surgeries type, the market is classified into coronary artery bypass grafting, transmyocardial laser revascularization, heart valve repair, arrhythmia treatment, aneurysm repair, and heart transplant.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/asia-pacific-cardiology-market
The companies which are contributing to the growth of the Asia-Pacific cardiology market include Abbott Laboratories, Boston Scientific Corp., Daiichi Sankyo Co. Ltd., F. Hoffmann-La Roche Ltd., General Electric Co., Johnson and Johnson Services Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co., Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Market Segmentation
Asia-Pacific Cardiology Market by Device Type
- Angioplasty
- Cardiovascular stents
- Cardiovascular catheters
- Cardiac rhythm management
- Cardiovascular assistive devices
Asia-Pacific Cardiology Market by Mechanism
- Antithrombotic drugs
- Antidyslipidemic drugs
- Antihypertensive drugs
- Anti-stroke drugs
Asia-Pacific Cardiology Market by Surgeries Type
- Beta blockers
- Beta agonists
- Alpha blockers
- Alpha agonists
- Sodium channel blockers
- Calcium channel blockers
- Vasodilators
- Renin inhibitors
- Angiotensin receptor blockers
- Diuretics
- Thrombolytics
Asia-Pacific Cardiology Market by Drug Type
- Coronary artery bypass grafting
- Transmyocardial laser revascularization
- Heart valve repair
- Arrhythmia treatment
- Aneurysm repair
- Heart transplant
Regional Analysis
- China
- India
- Japan
- Rest of Asia-Pacific
Company Profiles
- Abbott Laboratories
- Boston Scientific Corp.
- Daiichi Sankyo Co. Ltd.
- Hoffmann-La Roche Ltd.
- General Electric Co.
- Johnson and Johnson Services Inc.
- Medtronic PLC
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Pinnacle Biomed Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co., Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
